GBS Inc. (NYSE:GBS) major shareholder Science Biosensor Diagnos Life sold 45,152 shares of the firm’s stock in a transaction dated Friday, September 17th. The stock was sold at an average price of $3.29, for a total transaction of $148,550.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Shares of NYSE:GBS opened at $2.80 on Wednesday. The stock has a 50 day moving average price of $3.24 and a 200-day moving average price of $3.99. GBS Inc. has a 52-week low of $2.44 and a 52-week high of $14.24.
Institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new position in GBS during the second quarter valued at $98,000. Bridgeway Capital Management LLC increased its stake in shares of GBS by 555.6% in the 2nd quarter. Bridgeway Capital Management LLC now owns 118,000 shares of the company’s stock worth $465,000 after acquiring an additional 100,000 shares in the last quarter. Goldman Sachs Group Inc. bought a new position in shares of GBS in the 2nd quarter worth about $77,000. Anson Funds Management LP purchased a new position in GBS during the 2nd quarter valued at about $2,251,000. Finally, Geode Capital Management LLC bought a new stake in GBS during the second quarter worth about $43,000. Institutional investors and hedge funds own 6.69% of the company’s stock.
GBS Inc operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. The company also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers.
Featured Story: What is dividend yield?
Receive News & Ratings for GBS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GBS and related companies with MarketBeat.com's FREE daily email newsletter.